These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19759113)

  • 1. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging.
    Hofman MS; Smeeton NC; Rankin SC; Nunan T; O'Doherty MJ
    J Nucl Med; 2009 Oct; 50(10):1594-7. PubMed ID: 19759113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed Tomography Observer Agreement in Staging Malignant Lymphoma.
    de Jong A; Kwee TC; Quarles van Ufford HM; Beek FJ; Quekel LG; de Klerk JM; Zijlstra JM; Fijnheer R; Ludwig I; Kersten MJ; Stoker J; Nievelstein RA
    J Comput Assist Tomogr; 2016; 40(2):261-5. PubMed ID: 26599962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma.
    Hofman MS; Smeeton NC; Rankin SC; Nunan T; O'Doherty MJ
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):194-9. PubMed ID: 18828012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/MRI for the evaluation of patients with lymphoma: initial observations.
    Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
    AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard.
    Littooij AS; Kwee TC; Barber I; Granata C; Vermoolen MA; Enríquez G; Zsíros J; Soh SY; de Keizer B; Beek FJ; Hobbelink MG; Bierings MB; Stoker J; Nievelstein RA
    Eur Radiol; 2014 May; 24(5):1153-65. PubMed ID: 24563179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information.
    Arimoto MK; Nakamoto Y; Higashi T; Ishimori T; Ishibashi M; Togashi K
    Acta Radiol; 2018 Oct; 59(10):1218-1224. PubMed ID: 29333861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging.
    Punwani S; Taylor SA; Bainbridge A; Prakash V; Bandula S; De Vita E; Olsen OE; Hain SF; Stevens N; Daw S; Shankar A; Bomanji JB; Humphries PD
    Radiology; 2010 Apr; 255(1):182-90. PubMed ID: 20308456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
    Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
    Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
    Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study.
    Sher AC; Seghers V; Paldino MJ; Dodge C; Krishnamurthy R; Krishnamurthy R; Rohren EM
    AJR Am J Roentgenol; 2016 Mar; 206(3):623-31. PubMed ID: 26901021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
    Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
    Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET-CT and diagnostic CT: the synergy of metabolic and morphological data in onco-haematology.
    Ricard F; Giammarile F; Tychyj-Pinel C; Houzard C; Decullier E; Chateau F; Manichon AF; Orliaguet I; Michallet AS; Salles G; Valette PJ; Réty F
    Diagn Interv Imaging; 2014 Jan; 95(1):55-62. PubMed ID: 24012287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma.
    de Jong PA; van Ufford HM; Baarslag HJ; de Haas MJ; Wittebol SH; Quekel LG; de Klerk JM
    AJR Am J Roentgenol; 2009 Mar; 192(3):745-53. PubMed ID: 19234273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.